Cardiac manifestations in a two‑generation family with Fabry disease (RCD code: III‑2B.2a)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2014, Vol 1, Issue 8
Abstract
Fabry disease (FD), which is also called angiokeratoma corporis difusum, ceramide trihexosidosis, and Anderson-Fabry disease, is an X-linked inborn error of metabolism of glycosphingolipid pathway. It is caused by the deficiency of the the lysosomal enzyme – hydrolasealpha-galactosidase A, which results in the accumulation and subsequent tissue deposition of globotriaosylceramide, the glycolipid substrate for alpha-galactosidase A. The incidence of the disease varies between 1:17,000 to 1:117,000 males in the Caucasian populations. The disease is less common among women, and if present the symptoms are milder. Enzyme replacement therapy of the agalsidase-A or agalsidase-ß offers a specific treatment for patients with FD. Since 2001 the ERT, using recombinant human alpha-galactosidase A, has become the most efficient and specific therapy, which address the underlying defect of FD. The guidelines on the ERT greatly vary among countries, the main reason being the high cost of this treatment. Pediatric patients firstly suffer from neurological involvement, manifesting as a persistent, neuropathic pain of the extremities, often misdiagnosed as a “growing pain”, as well as gastrointestinal disorders(diarrhea, nausea, vomiting). In the later stages other organs are becoming involved causing multi-organ failure renal insufficiency, cardiovascular impairment, cerebrovascular incidences, cutaneous changes (teleangiectasias, angiokeratomas and lymphoedema), malfunction of sensations organs (cornea verticillata, retinal vascular tortuosity) and other symptom like anhidrosis, sweating problems, heat collapse or depression. JRCD 2014; 1 (8): 27–31
Authors and Affiliations
Paweł Rubiś, Sylwia Wiśniowska-Śmiałek, Barbara Biernacka-Fijałkowska, Magdalena Kostkiewicz, Agata Leśniak-Sobelga, Piotr Podolec
Keywords
Related Articles
- EP ID EP245414
- DOI 10.20418/jrcd.vol1no8.155
- Views 104
- Downloads 0
Report from the 65th American College of Cardiology Congress 2016 in Chicago, USA
Having visited several European Society of Cardiology (ESC) Congresses, this time the plan was to explore famous American College of Cardiology (ACC) annual Congress. For a long time American way of making science domina...
Current views on the use of interferons in the treatment of polycythaemia vera
Interferon alpha is a molecule associated with stimulation of immune system cells, resulting in an anti‐proliferative and immunomodulatory effect. It has been demonstrated that interferon reduces the number of platelets,...
Heart in Fabry Disease
Fabry disease is one of the lysosomal storage disorders, that results from progressive multiorgan accumulation of glycoproteins. It is caused by mutations of the GLA gene, which encodes alpha-galactosidase A. The incide...
Exercise ECG unmasked Brugada sign: manifestation of the risk of sports‑associated sudden cardiac arrest (RCD code: V‑1A.1)
Sports‑associated sudden cardiac arrest (SCA) constitutes an important problem. Causes of SCA during sport activities include Brugada syndrome (BrS) among others. We describe a 29‑year‑old male, without a history of card...
Concussion of an athlete ́s heart – a case report of blunt chest trauma‐associated loss of consciousness in a professional soccer player (RCD code: V-4O)
We present a case of cardiac concussion (commotio cordis) resulting from blunt chest trauma injury in a professional athlete. The soccer player received frontal injury to the chest caused by another player’s knee during...